Sign In
Buy SNY
$43.75
-0.230 (-0.523%)
At Close: Jul 21, 2026
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
01:56pm, Wednesday, 11'th Sep 2024
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
01:05am, Wednesday, 11'th Sep 2024
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary an
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary e
While reported use of Sanofi/Regeneron's Dupixent has declined with the adoption of LEO's Adbry, Pfizer's Cibinqo, and AbbVie's Rinvoq, the overall population receiving advanced treatments is on the r
MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science th
Why Sanofi Stock Was Robustly Healthy Today
06:16pm, Tuesday, 03'rd Sep 2024
The pharmaceutical-sector mainstay published news about its investigational multiple sclerosis drug. It did well in one trial but was less impressive in two others.
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
09:35am, Monday, 02'nd Sep 2024
Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
Sanofi MS drug tolebrutinib misses goal in relapsing disease trials
01:12am, Monday, 02'nd Sep 2024
Sanofi's most advanced multiple sclerosis (MS) drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, dimming the prospects for a widely-pursued clas
Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
01:57pm, Monday, 19'th Aug 2024
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comp
Three Biotech Stocks to Buy for the "Golden Age of Medicine"
01:49pm, Monday, 19'th Aug 2024
A year ago, medical experts and Nobel Laureates interviewed by The New York Times proclaimed "a Golden Age of Medicine" is here.
3 Biotech Stocks to Buy on the Dip: August 2024
06:00am, Thursday, 15'th Aug 2024
With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
05:00am, Wednesday, 14'th Aug 2024
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi Led by long-standing investor EcoR1 Capital with participation from addition
Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
05:05am, Tuesday, 06'th Aug 2024
AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.
